HALFAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Halfan, and what generic alternatives are available?
Halfan is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in HALFAN is halofantrine hydrochloride. Additional details are available on the halofantrine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HALFAN?
- What are the global sales for HALFAN?
- What is Average Wholesale Price for HALFAN?
Summary for HALFAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 127 |
| Patent Applications: | 233 |
| DailyMed Link: | HALFAN at DailyMed |
US Patents and Regulatory Information for HALFAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | HALFAN | halofantrine hydrochloride | TABLET;ORAL | 020250-001 | Jul 24, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
